Toxicity management of regorafenib in patients with gastro-intestinal stromal tumour (GIST) in a tertiary cancer centre

BACKGROUND: Regorafenib is a multi-kinase inhibitor approved as third line treatment for metastatic GIST. Dose limiting toxicities are frequently seen and many patients require dose reductions. This study aimed to evaluate regorafenib toxicities and their management in a real-world GIST population....

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Sarcoma Res
Glavni autori: Chamberlain, Florence, Farag, Sheima, Williams-Sharkey, Constance, Collingwood, Cecilia, Chen, Lucia, Mansukhani, Sonia, Engelmann, Bodil, Al-Muderis, Omar, Chauhan, Dharmisha, Thway, Khin, Fisher, Cyril, Jones, Robin L., Gennatas, Spyridon, Benson, Charlotte
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2020
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6942401/
https://ncbi.nlm.nih.gov/pubmed/31911828
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13569-019-0123-4
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items